Torrent Pharmaceuticals Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Torrent Pharmaceuticals and Zydus Lifesciences have entered a licensing agreement to co-market semaglutide injection in India, targeting diabetes and weight management. Torrent will leverage its market presence and pay an upfront licensing fee to Zydus.

Torrent Pharma Partners with Zydus for Diabetes Drug - 18 Mar, 2026

Torrent Pharmaceuticals has demonstrated robust financial growth, with significant increases in sales, EBITDA, and net profits. The stock is currently bullish, with a target price of ₹4,650.

Torrent Pharmaceuticals Shows Strong Growth and Bullish Trend - 10 Mar, 2026

Citi has reiterated its Buy rating on Torrent Pharmaceuticals, increasing the target price to Rs 5,100, driven by expected synergies from the JB Chemicals acquisition and strong growth in key markets. The company anticipates significant cost savings and revenue growth, with a positive outlook for EBITDA margins and net debt reduction by FY30.

Citi Upgrades Torrent Pharma Target Price to Rs 5,100 - 09 Mar, 2026

Torrent Pharmaceuticals Ltd is experiencing a strong bullish trend, gaining for five consecutive sessions and showing significant yearly growth of 48.39%. Analysts suggest a target of ₹4760.

Torrent Pharmaceuticals Continues Upward Trend - 25 Feb, 2026

Torrent Pharmaceuticals Ltd sees a share price increase to ₹4,423, with Macquarie initiating coverage at a target of Rs 5,000. The company anticipates strong growth and cost synergies following the JB Pharma acquisition.

Torrent Pharma Gains on Positive Analyst Ratings and Growth Prospects - 24 Feb, 2026

Macquarie has initiated coverage on Torrent Pharmaceuticals with an Outperform rating and a target price of Rs 5,000, highlighting growth potential from acquisitions.

Macquarie Initiates Outperform Rating for Torrent Pharma - 23 Feb, 2026

Brokerages have set varying target prices for Torrent Pharmaceuticals, with Nuvama at Rs 4,700, highlighting strong domestic performance and margin expansion potential.

Torrent Pharmaceuticals Target Prices Set by Brokerages - 20 Feb, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Foreign Institutions have increased holdings from 15.92% to 16.13% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 3 months, TORNTPHARM stock has moved up by 11.9%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

In the last 3 years, TORNTPHARM has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

In the last 1 year, TORNTPHARM has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

Revenue is up for the last 5 quarters, 2.84K Cr → 3.29K Cr (in ₹), with an average increase of 3.6% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 4 quarters, 498.0 Cr → 635.0 Cr (in ₹), with an average increase of 7.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Promoters holdings remained unchanged at 68.31% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 6.49% to 6.42% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Mutual Funds have decreased holdings from 5.12% to 4.83% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

NIFTY 100

S&P BSE Momentum

Nifty100 Low Volatility 30

S&P BSE 250 LargeMidCap

Nifty 200

S&P BSE Quality

Nifty100 Eq Weig

S&P BSE Dividend Stability

S&P BSE 100 LargeCap TMC

BSE 200

Nifty LargeMidcap 250

Nifty Healthcare

BSE 500

Nifty 500

NIFTY PHARMA

BSE Healthcare

Nifty Next 50

HDFC Large Cap Fund -Direct Plan - Growth Option

Axis Large Cap Fund Direct Plan Growth

UTI Flexi Cap Fund - Growth Option - Direct

Franklin India Large Cap Fund Direct Growth

Canara Robeco Large Cap Fund Direct Plan Growth

Torrent Pharmaceuticals Ltd’s net profit jumped 26.24% since last year same period to ₹635.00Cr in the Q3 2025-2026. On a quarterly growth basis, Torrent Pharmaceuticals Ltd has generated 7.45% jump in its net profits since last 3-months.

Torrent Pharmaceuticals Ltd Earnings Results

In the quarter ending December 2025, Torrent Pharmaceuticals Ltd has declared dividend of ₹29.00 per share on 13 Feb 2026 - translating a dividend yield of 0.83%.

Name	Value	Action
MACD level (12,26)	-1.66	Bullish
CCI (20)	-105.92	Bullish
RSI (14)	47.47	Neutral
Momentum (10)	2.6	Bullish
ADI (14)	20.9	Neutral
Ultimate Oscillator (7,14,28)	51.61	Neutral

Name	Value	Action
SMA (20)	4266.6	Bullish
EMA (20)	4268.31	Bearish
VWMA (20)	4266.62	Bullish
SMA (50)	4273.15	Bearish
EMA (50)	4272.04	Bearish
SMA (200)	4274.37	Bearish
EMA (200)	4270.88	Bearish
KAMA (200)	4276.38	Bearish
DEMA (200)	4282.35	Bearish

Torrent Pharmaceuticals Ltd (TORNTPHARM)

Summary

Overall

Oscillators

Moving Averages